View in EDS HTML Full Text PDF Full Text

Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial

Saved in:
Bibliographic Details
Title: Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial
Authors: Nasca, Vincenzo1 (AUTHOR), Bergamo, Francesca2 (AUTHOR), Foltran, Luisa3 (AUTHOR), Antonuzzo, Lorenzo4,5 (AUTHOR), Bencardino, Katia6 (AUTHOR), Dell'Aquila, Emanuela7 (AUTHOR), Corallo, Salvatore8,9 (AUTHOR), Spallanzani, Andrea10 (AUTHOR), Brunetti, Oronzo11 (AUTHOR), Spada, Daniele12 (AUTHOR), Tamberi, Stefano13 (AUTHOR), Cella, Chiara Alessandra14 (AUTHOR), Avallone, Antonio15 (AUTHOR), Fornaro, Lorenzo16 (AUTHOR), Di Donato, Samantha17 (AUTHOR), Strippoli, Antonia18 (AUTHOR), Puccini, Alberto19,20 (AUTHOR), Tamburini, Emiliano21 (AUTHOR), Palermo, Federica1 (AUTHOR), Morano, Federica1 (AUTHOR)
Source: BMC Cancer. 4/8/2025, Vol. 25 Issue 1, p1-11. 11p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:14712407
DOI:10.1186/s12885-025-14063-6